Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD

Activation of fibroblast growth factor receptor (FGFR)-dependent signalling by FGF23 may contribute to the complex pathogenesis of left ventricular hypertrophy (LVH) in chronic kidney disease (CKD). Pan FGFR blockade by PD173074 prevented development of LVH in the 5/6 nephrectomy rat model of CKD, but its ability to treat and reverse established LVH is unknown. CKD was induced in rats by 5/6 nephrectomy. Two weeks later, rats began treatment...